Bank of New York Mellon Corp Has $14.69 Million Position in CRISPR Therapeutics AG $CRSP

Bank of New York Mellon Corp lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 288.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 301,959 shares of the company’s stock after purchasing an additional 224,257 shares during the quarter. Bank of New York Mellon Corp owned about 0.35% of CRISPR Therapeutics worth $14,687,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Envestnet Asset Management Inc. increased its position in shares of CRISPR Therapeutics by 21.5% during the first quarter. Envestnet Asset Management Inc. now owns 68,058 shares of the company’s stock worth $2,316,000 after acquiring an additional 12,025 shares in the last quarter. Cerity Partners LLC bought a new position in CRISPR Therapeutics during the 1st quarter worth about $216,000. CWM LLC raised its stake in shares of CRISPR Therapeutics by 1,308.5% in the 1st quarter. CWM LLC now owns 3,803 shares of the company’s stock valued at $129,000 after purchasing an additional 3,533 shares during the period. Private Advisor Group LLC lifted its holdings in shares of CRISPR Therapeutics by 27.5% in the first quarter. Private Advisor Group LLC now owns 108,418 shares of the company’s stock valued at $3,689,000 after purchasing an additional 23,382 shares in the last quarter. Finally, Kestra Private Wealth Services LLC boosted its position in shares of CRISPR Therapeutics by 6.6% during the first quarter. Kestra Private Wealth Services LLC now owns 21,991 shares of the company’s stock worth $748,000 after buying an additional 1,355 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 50,895 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares of the company’s stock, valued at $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of the firm’s stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the sale, the general counsel owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 56,213 shares of company stock worth $3,810,458. Corporate insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

CRSP has been the topic of a number of recent research reports. JPMorgan Chase & Co. assumed coverage on CRISPR Therapeutics in a research report on Thursday, September 18th. They issued an “overweight” rating and a $70.00 target price on the stock. Wells Fargo & Company set a $75.00 target price on shares of CRISPR Therapeutics in a research report on Monday, October 13th. Needham & Company LLC cut their price target on shares of CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Royal Bank Of Canada raised their price objective on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a report on Tuesday, November 11th. Finally, Chardan Capital reissued a “buy” rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. Eleven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $67.84.

CRISPR Therapeutics Stock Up 5.3%

NASDAQ:CRSP opened at $55.32 on Tuesday. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $78.48. The firm has a market capitalization of $5.27 billion, a price-to-earnings ratio of -9.90 and a beta of 1.89. The stock’s 50 day moving average price is $62.96 and its two-hundred day moving average price is $53.87.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, November 10th. The company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The company had revenue of $0.89 million during the quarter, compared to the consensus estimate of $8.74 million. Equities research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.